Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 11:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–2 of 2 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: AChR-Ab Seropositive Generalized Myasthenia Gravis Clear all

Recruiting No phase listed Observational

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

NCT07294170

View directory record Official record

Conditions: Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG), AChR-Ab Seropositive Generalized Myasthenia Gravis
Interventions: Efgartigimod IV, Empasiprubart IV; Biological
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older

Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Carlsbad, California • Miami, Florida • Columbia, Maryland + 2 more

Source: ClinicalTrials.gov public record

Updated Apr 22, 2026 · Synced May 21, 2026, 11:11 PM EDT

Recruiting Phase 2 Interventional

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

NCT07284420

View directory record Official record

Conditions: AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG)
Interventions: Efgartigimod IV, Empasiprubart IV; Biological
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older

Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Carlsbad, California • Miami, Florida • Amherst, New York + 2 more

Source: ClinicalTrials.gov public record

Updated Apr 22, 2026 · Synced May 21, 2026, 11:11 PM EDT